Your browser is no longer supported. Please, upgrade your browser.
Settings
BHVN Biohaven Pharmaceutical Holding Company Ltd. daily Stock Chart
BHVN [NYSE]
Biohaven Pharmaceutical Holding Company Ltd.
Index- P/E- EPS (ttm)-6.05 Insider Own7.70% Shs Outstand37.99M Perf Week-2.79%
Market Cap1.59B Forward P/E- EPS next Y-5.00 Insider Trans-22.92% Shs Float23.18M Perf Month8.35%
Income-201.90M PEG- EPS next Q-1.18 Inst Own74.10% Short Float13.59% Perf Quarter57.02%
Sales- P/S- EPS this Y-91.00% Inst Trans0.29% Short Ratio7.36 Perf Half Y59.97%
Book/sh2.93 P/B14.27 EPS next Y13.80% ROA-120.20% Target Price49.57 Perf Year71.31%
Cash/sh2.74 P/C15.24 EPS next 5Y- ROE-137.20% 52W Range16.50 - 44.28 Perf YTD54.93%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.60% Beta-
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin- 52W Low153.33% ATR1.83
Employees49 Current Ratio6.80 Sales Q/Q- Oper. Margin- RSI (14)62.49 Volatility4.38% 4.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-33.60% Profit Margin- Rel Volume0.50 Prev Close41.65
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume428.30K Price41.80
Recom1.90 SMA202.62% SMA5017.37% SMA20037.64% Volume212,171 Change0.36%
Jul-03-18Reiterated Needham Buy $36 → $48
Jul-02-18Reiterated Needham Buy $36 → $48
Apr-05-18Downgrade Barclays Overweight → Equal Weight $30 → $25
Feb-22-18Reiterated Canaccord Genuity Buy $30 → $39
Dec-15-17Initiated Canaccord Genuity Buy $30
Oct-03-17Reiterated Needham Buy $43 → $36
Jun-28-18 12:30PM  Biohaven Pharma's New Migraine Drug Shows Promise in Late-Stage Test Results TheStreet.com
07:20AM  Free Technical Reports on Cerus and Three Additional Biotech Equities ACCESSWIRE
03:00AM  Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting PR Newswire
Jun-21-18 07:15AM  Blog Exposure - Biohaven Signs Royalty Funding and Stock Purchase Agreements with Royalty Pharma ACCESSWIRE
Jun-19-18 08:37AM  Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) Is Expected To Breakeven Simply Wall St.
Jun-18-18 08:06PM  Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million PR Newswire
Jun-13-18 07:30AM  Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region PR Newswire
Jun-05-18 03:00AM  Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual Scientific Meeting 2018 PR Newswire
May-16-18 08:35AM  What Do Analysts Think About Biohaven Pharmaceutical Holding Company Ltds (NYSE:BHVN) Earnings Trend? Simply Wall St.
May-15-18 04:15PM  Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results PR Newswire
May-09-18 07:35AM  Our Free Research Report on Biogen and More Biotech Stocks ACCESSWIRE
03:00AM  Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) PR Newswire
Apr-22-18 10:00PM  Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine PR Newswire
Apr-19-18 07:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within BIOHAVEN PHARM, WEC Energy Group, Axon Enterprise, Tutor Perini, Waste Management, and Twenty-First Century Fox New Research Emphasizes Economic Growth GlobeNewswire
03:00AM  Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles PR Newswire
Apr-05-18 09:52AM  Kleo Pharmaceuticals Selected to Present at Biotech Innovation Conference PR Newswire
Apr-03-18 03:00AM  Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer PR Newswire
Mar-28-18 07:40AM  Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant ACCESSWIRE +8.18%
Mar-27-18 04:34PM  Canaccord Sees An 'Intriguing Setup' In Biohaven Following Reaction To Phase 3 News Benzinga
06:47AM  Heres Whats Moving AnaptysBio and Biohaven Pharmaceutical Market Exclusive
Mar-26-18 04:13PM  Biohaven Craters By A Third On Migraine Drug Study Rivaling Allergan Investor's Business Daily -7.27%
12:31PM  Here's Why Biohaven Pharmaceutical Holding Co Ltd's Getting Hammered Today Motley Fool
12:19PM  Biohaven's IPO Roadshow Fantasy Meets Grimmer Reality Bloomberg
11:15AM  Biohaven plunges as investors pit migraine data against Allergan's drug Reuters
09:05AM  Biohaven shares drop 23% after migraine drug trial results MarketWatch
03:00AM  Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine PR Newswire
Mar-20-18 07:50PM  Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN): Is Breakeven Near? Simply Wall St.
Mar-13-18 10:42AM  Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options Zacks
Mar-12-18 03:00AM  Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading Institutional Investors PR Newswire
Mar-06-18 04:30PM  Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial And Business Results PR Newswire -7.59%
03:00AM  Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine PR Newswire
Mar-01-18 03:00AM  Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis® Orally Dissolving Tablet PR Newswire
Feb-21-18 03:00AM  Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists PR Newswire
Feb-08-18 07:40AM  Analysis: Positioning to Benefit within Great Plains Energy, Flowers Foods, Hasbro, BIOHAVEN PHARM, Vonage, and NOW Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -6.58%
Feb-01-18 07:35AM  Investor Expectations to Drive Momentum within Park National, Loral Space and Communications, Allegiance Bancshares, BIOHAVEN PHARM, Equifax, and PayPal Discovering Underlying Factors of Influence GlobeNewswire -5.38%
Jan-18-18 03:00AM  Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist PR Newswire +7.58%
Jan-11-18 07:40AM  Wired News Biohaven Pharmaceutical Shares Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis Orally Dissolving Tablet ACCESSWIRE
Jan-09-18 03:00AM  Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet PR Newswire
Dec-21-17 03:00AM  Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder PR Newswire
Nov-27-17 03:00AM  Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant PR Newswire
Nov-20-17 07:40AM  Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine ACCESSWIRE
03:00AM  Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine PR Newswire
Nov-16-17 03:00AM  Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine PR Newswire +5.93%
Nov-14-17 06:02PM  Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results PR Newswire
Nov-13-17 03:00AM  Biohaven Expands Finance Team With Appointment Of Senior Vice President PR Newswire
Nov-06-17 03:00AM  Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223 PR Newswire
Nov-01-17 04:00AM  Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with ALS Benzinga
03:00AM  Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis (ALS) PR Newswire
Oct-30-17 03:00AM  Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute PR Newswire
Oct-26-17 07:30AM  Corporate News Blog - US FDA Green Signals Clinical Investigation of Biohaven Pharma's Trigriluzole For Treatment Of OCD ACCESSWIRE
Oct-25-17 03:00AM  Biohaven Adds Clifford Bechtold as Chief Operating Officer PR Newswire
Oct-24-17 03:00AM  Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder PR Newswire
Oct-03-17 04:25PM  Why This Biotech Suffered A 2-Day Headache On Rare-Disease Trial Investor's Business Daily -6.97%
Oct-02-17 12:24PM  Here's Why Biohaven Pharmaceutical Stock Fell as Much as 28.6% Today Motley Fool
06:30AM  Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial PR Newswire
Sep-15-17 03:00AM  Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease PR Newswire
Sep-11-17 03:00AM  Biohaven To Provide Development Program Update At The Morgan Stanley 15th Annual Global Healthcare Conference PR Newswire
Aug-30-17 07:30AM  [$$] Zinsli's Take: A Milestone for Post-IPO Companies Is In Sight The Wall Street Journal
Aug-14-17 06:44AM  Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results PR Newswire
Aug-07-17 03:00AM  Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 PR Newswire
Aug-04-17 03:00AM  Biohaven Appoints Julia P. Gregory to Board of Directors PR Newswire
Jul-31-17 03:00AM  Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine PR Newswire
Jul-24-17 03:00AM  Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine PR Newswire
Jul-18-17 03:00AM  PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology PR Newswire
Jul-13-17 03:00AM  Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs PR Newswire
Jul-12-17 09:50AM  IPO Market Back On Track: ETFs to Tap Zacks
Jul-09-17 12:22PM  [$$] Clinical Development News, July 3-7 The Wall Street Journal
Jul-06-17 03:00AM  Biohaven's BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome PR Newswire
Jun-23-17 05:00PM  Biohaven Added to Russell Microcap® Index PR Newswire
Jun-22-17 03:00AM  Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives PR Newswire -5.00%
Jun-19-17 04:33PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
04:27PM  Biotech IPO Rides Sectorwide Boom To Breakout Monday Investor's Business Daily
Jun-16-17 06:00AM  Biohaven Pharmaceuticals Reports First Quarter 2017 Financial and Business Results PR Newswire +10.83%
Jun-09-17 03:00AM  Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer PR Newswire
May-30-17 03:00AM  Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole PR Newswire
May-19-17 07:13PM  [$$] Clinical Development News, May 15-19 The Wall Street Journal
May-18-17 07:30AM  [$$] Some Biotech Companies Making the Cut in Narrower IPO Market The Wall Street Journal
May-15-17 03:00AM  Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA PR Newswire
May-11-17 10:40PM  Biohaven Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
May-09-17 09:29AM  Opening Bell, May 9, 21017 CNBC Videos
09:15AM  Today's Bell Ringer, May 9, 2017 CNBC Videos
May-07-17 10:31AM  IPOs This Week: Manufacturing Firm Gardner Denver Seeks $1 Billion 24/7 Wall St.
May-04-17 08:56AM  Biohaven Pharmaceutical raises $168 million in initial public offering MarketWatch
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gentile KimberlyVP of OperationsJun 15Option Exercise0.6112,5007,62512,500Jun 19 04:43 PM
Gentile KimberlyVP of OperationsJun 15Sale40.0212,500500,2500Jun 19 04:43 PM
Berman RobertChief Medical OfficerJun 12Sale37.3920,257757,443234,551Jun 12 04:12 PM
Berman RobertChief Medical OfficerJun 11Sale36.0975,4922,724,160250,827Jun 12 04:12 PM
Berman RobertChief Medical OfficerJun 08Sale36.018,406302,700320,692Jun 12 04:12 PM
Berman RobertChief Medical OfficerJun 07Sale36.012,50090,025327,427Jun 07 04:29 PM
Berman RobertChief Medical OfficerJun 06Sale36.0116,983611,558329,430Jun 07 04:29 PM
Berman RobertChief Medical OfficerJun 05Sale36.026,362229,131343,038Jun 07 04:29 PM
Doogan DeclanDirectorJun 05Sale35.4149,7631,762,2851,196,002Jun 06 04:19 PM
Doogan DeclanDirectorJun 04Sale35.0539,4531,382,8281,245,765Jun 06 04:19 PM
Doogan DeclanDirectorJun 01Sale35.0483,8982,939,7861,285,218Jun 01 05:29 PM
Coric VladChief Executive OfficerJun 01Sale35.0413,840484,954525,000Jun 01 05:26 PM
Doogan DeclanDirectorMay 31Sale35.0126,044911,8001,369,116Jun 01 05:29 PM
Coric VladChief Executive OfficerMay 31Sale35.0134,6191,212,011530,229Jun 01 05:26 PM
Engelhart JamesChief Financial OfficerMay 30Option Exercise0.615,0003,0505,000May 30 06:02 PM
Doogan DeclanDirectorMay 30Sale35.0084229,4701,395,160Jun 01 05:29 PM
Coric VladChief Executive OfficerMay 30Sale35.001,54153,935549,200Jun 01 05:26 PM
Engelhart JamesChief Financial OfficerMay 30Sale35.005,000175,0000May 30 06:02 PM
Berman RobertChief Medical OfficerMay 10Sale26.8235,000938,706348,000May 14 05:11 PM
Engelhart JamesChief Financial OfficerMay 07Sale27.672,50069,1750May 09 04:53 PM
Berman RobertChief Medical OfficerApr 10Sale24.6635,000863,132376,000Apr 12 05:02 PM
Berman RobertChief Medical OfficerMar 12Sale30.1135,0001,053,929404,000Mar 14 05:05 PM
Gentile KimberlyVP of OperationsMar 01Option Exercise0.615,0003,0505,000Mar 05 04:31 PM
Gentile KimberlyVP of OperationsMar 01Sale32.875,000164,3440Mar 05 04:31 PM
Engelhart JamesChief Financial OfficerFeb 21Sale29.6053815,9253,038Feb 23 05:52 PM
Gentile KimberlyVP of OperationsFeb 01Option Exercise0.615,0003,0505,000Feb 02 06:18 PM
Gentile KimberlyVP of OperationsFeb 01Sale32.785,000163,9000Feb 02 06:18 PM
Bailey GregoryDirectorJan 31Sale33.7150,0001,685,3522,475,101Feb 02 06:17 PM
Bailey GregoryDirectorJan 23Sale32.7916,000524,6402,525,101Jan 25 07:28 PM
PORTAGE BIOTECH INC.former 10% ownerJan 23Sale331520.0024,2778,048,311,04054,494Jan 24 07:01 PM
Engelhart JamesChief Financial OfficerJan 22Option Exercise0.6110,0006,10013,576Jan 24 07:00 PM
Engelhart JamesChief Financial OfficerJan 22Sale32.5010,000325,0003,576Jan 24 07:00 PM
Bailey GregoryDirectorJan 22Sale32.519,000292,5902,541,101Jan 23 06:57 PM
PORTAGE BIOTECH INC.former 10% ownerJan 19Sale30.0335,1191,054,79278,771Jan 24 07:01 PM
Bailey GregoryDirectorJan 19Sale30.3740,0001,214,8692,550,101Jan 23 06:57 PM
Doogan DeclanDirectorJan 18Sale28.2227,935788,2541,396,002Jan 18 06:57 PM
Doogan DeclanDirectorJan 17Sale26.5961,2561,628,6891,423,937Jan 18 06:57 PM
Doogan DeclanDirectorJan 16Sale26.6138,8671,034,3541,485,193Jan 18 06:57 PM
Bailey GregoryDirectorJan 16Sale26.5240,0001,060,8002,590,101Jan 18 06:37 PM
Doogan DeclanDirectorJan 12Sale26.3933,442882,5931,178,058Jan 12 07:00 PM
Doogan DeclanDirectorJan 11Sale26.2848,1381,265,2811,211,500Jan 12 07:00 PM
Doogan DeclanDirectorJan 10Sale27.6940,3621,117,6641,259,638Jan 12 07:00 PM
Berman RobertChief Medical OfficerJan 10Sale27.5235,000963,133466,000Jan 12 06:59 PM
PORTAGE BIOTECH INC.10% OwnerJan 09Sale30.0856,1571,688,9556,216,619Jan 09 06:23 PM
PORTAGE BIOTECH INC.10% OwnerJan 08Sale30.025,728171,9446,272,776Jan 09 06:23 PM
PORTAGE BIOTECH INC.10% OwnerJan 05Sale30.0322,996690,6736,278,504Jan 09 06:23 PM
Bailey GregoryDirectorJan 04Sale28.7716,976488,4001,170,299Jan 05 08:05 PM
PORTAGE BIOTECH INC.10% OwnerJan 04Sale28.624,350124,504124,371Jan 05 10:29 AM
Bailey GregoryDirectorJan 03Sale28.6833,024947,1281,187,275Jan 05 08:05 PM
PORTAGE BIOTECH INC.10% OwnerJan 03Sale28.6135,6501,020,0716,305,850Jan 04 04:15 PM
Gentile KimberlyVP of OperationsJan 02Option Exercise0.615,0003,0505,000Jan 03 05:28 PM
Gentile KimberlyVP of OperationsJan 02Sale27.605,000138,0000Jan 03 05:28 PM
Bailey GregoryDirectorDec 20Sale26.3139,4301,037,2901,220,299Dec 22 05:58 PM
Berman RobertChief Medical OfficerDec 19Sale24.1010,000241,000494,000Dec 20 05:57 PM
Berman RobertChief Medical OfficerDec 11Sale21.2825,000532,000502,000Dec 14 07:08 AM
Gentile KimberlyVP of OperationsDec 01Option Exercise0.615,0003,0505,000Dec 05 04:02 PM
Gentile KimberlyVP of OperationsDec 01Sale21.995,000109,9620Dec 05 04:02 PM
Bailey GregoryDirectorNov 30Sale25.473,03077,1741,259,729Dec 01 07:27 PM
Bailey GregoryDirectorNov 29Sale25.486,940176,8311,262,759Dec 01 07:27 PM
Bailey GregoryDirectorNov 27Sale25.9220,000518,4001,269,699Nov 28 07:19 PM
Bailey GregoryDirectorNov 24Sale26.0260015,6121,289,699Nov 28 07:19 PM
Berman RobertChief Medical OfficerNov 14Sale24.4433,664822,627522,000Nov 14 05:51 PM
Berman RobertChief Medical OfficerNov 13Sale25.6246,5871,193,380548,932Nov 14 05:51 PM
Engelhart JamesChief Financial OfficerNov 10Option Exercise0.618,9385,45212,514Nov 14 05:52 PM
Engelhart JamesChief Financial OfficerNov 10Sale26.288,938234,8913,576Nov 14 05:52 PM
Berman RobertChief Medical OfficerNov 10Sale26.3152,3261,376,697586,201Nov 14 05:51 PM
Engelhart JamesChief Financial OfficerNov 09Option Exercise0.6121,60013,17625,176Nov 14 05:52 PM
Engelhart JamesChief Financial OfficerNov 09Sale26.7021,600576,6703,576Nov 14 05:52 PM
Berman RobertChief Medical OfficerNov 09Sale26.6027,423729,361628,062Nov 14 05:51 PM
Tilton JohnChief Commercial OfficerNov 01Option Exercise9.2930,000278,70030,000Nov 02 05:55 PM
Gentile KimberlyVP of OperationsNov 01Option Exercise0.615,0003,0505,000Nov 02 05:57 PM
Gentile KimberlyVP of OperationsNov 01Sale29.285,000146,3850Nov 02 05:57 PM
Tilton JohnChief Commercial OfficerNov 01Sale29.2530,000877,5860Nov 02 05:55 PM
Coric VladChief Executive OfficerNov 01Sale29.2450,0001,462,203575,000Nov 02 05:54 PM
Coric VladChief Executive OfficerOct 31Sale29.50100,0002,949,632600,000Nov 02 05:54 PM